Incorporation of a doctor to the R&D&i within the "Torres Quevedo" program

2018 Call


No votes yet
 
Related
ROVI tops the Sustainalytics sustainability ranking for the pharmaceutical subindustry worldwide Laboratorios Farmacéuticos ROVI...
2 min
01/08/2022
ROVI REPORTS OPERATING REVENUE GROWTH OF 31% AND NET PROFIT GROWTH OF 58%   Operating revenue increased by 31% to 380.4...
3 min
27/07/2022
Madrid, 19th July 2022 The European Investment Bank (EIB) is providing Laboratorios Farmacéuticos Rovi (ROVI) with a new EUR 50 million...
4 min
19/07/2022